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Abstract:  
Heart failure with reduced ejection fraction (HFrEF) is a deadly and disabling disease.  A key 
derangement contributing to impaired exercise performance in HFrEF is decreased nitric oxide 
(NO) bioavailability.  Scientists recently discovered the inorganic nitrate pathway for increasing 
NO. This has advantages over organic nitrates and NO synthase production of NO.  Small 
studies using beetroot juice as a source of inorganic nitrate demonstrate its power to improve 
exercise performance in HFrEF.  A larger-scale trial is now underway to determine if inorganic 
nitrate may be a new arrow for physicians’ quiver of HFrEF treatments. 
  
Keywords: Nitric oxide, inorganic nitrate, exercise performance, heart failure, muscle power, 
peak oxygen consumption  
 
Abbreviations: HF = heart failure, HFrEF = heart failure with reduced ejection fraction, cGMP = 
cyclic guanine monophosphate, sGC = soluble guanylyl cyclase, NO = nitric oxide, NO3- = 
nitrate, NO2- = nitrite, NOS = nitric oxide synthase, ROS = reactive oxygen species, ALDH-2 = 
aldehyde dehydrogenase, PDE5 = phosphodiesterase 5, PKG = cGMP-dependent protein 
kinase, SERCA = sarcoendoplasmic reticulum calcium transport ATPase.  
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Introduction. 
Heart failure (HF), specifically heart failure with reduced ejection fraction (HFrEF), is a major 
public health problem. HFrEF is not only a deadly but also a disabling disease.  This disability is 
thought to relate, at least in part, to impaired nitric oxide (NO) bioavailability.  Recent discoveries 
regarding the inorganic nitrate pathway as a novel source of NO for the body have led to a 
burgeoning field of research leveraging this pathway for the treatment of diseases including 
HFrEF. This pathway has particular advantages over other mechanisms for the production of NO.  
Moreover, most preliminary studies show that inorganic nitrate can increase both muscle power 
and aerobic exercise performance, which should improve patients’ ability to perform their activities 
of daily living.  Continued research is ongoing to determine if inorganic nitrate may be a novel, 
effective treatment for HFrEF.  
 
Significance of heart failure with reduced ejection fraction (HFrEF).  
Heart failure is a public health problem of epidemic proportion.  It affects ~6 million people in the 
U.S. and ~23 million worldwide [1, 2]. Unfortunately, these numbers are increasing.  Adults over 
age 40 y now have a 1 in 5 chance of developing HF in their lifetime.  Moreover, HF costs ~$39.1 
billion annually in the U.S. alone. The human cost is great as well: 40% of patients die within 1 y 
of diagnosis and 5 y survival is only 35% [1].  In addition, those who live with HF often endure 
significant disability and decreased quality of life. Given the costly and disabling nature of HF and 
its tremendous impact on quality of life, any improvement in exercise performance would be of 
enormous benefit to patients with this disease. 
 HFrEF is a particularly disabling disease in part because it impairs patients’ capacity to 
perform aerobic exercise and increases ventilatory effort, resulting in dyspnea. Indeed, the main  
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classification systems used to evaluate HFrEF stratify the severity of disease based on the 
physical limitations it imposes. For example, as the New York Heart Association class of HF 
increases (from I to IV), the limitations in aerobic exercise increase. Demonstrating impaired 
aerobic exercise tolerance in HF is an important component of declaring a patient “disabled” due 
to HF.  Moreover, impaired aerobic capacity during exercise is one of the key tests used to 
evaluate HFrEF patients for cardiac transplantation and to predict mortality [3, 4]. The lower the 
peak oxygen consumption (V̇O2peak) in HF patients, the worse the prognosis and the worse the 
disability.  
 Decreased skeletal muscle power (speed x force of contraction) also impairs quality of life 
and predicts increased mortality. Most typical daily activities require muscle power, as opposed 
to aerobic capacity. Getting out of bed, rising from a chair, opening a jar, lifting groceries, picking 
up a child, and climbing stairs are all activities that require power. Although it is well-known that 
HFrEF impairs aerobic capacity, it is less widely appreciated that HFrEF also decreases muscle 
strength and power [5, 6]. HFrEF patients are less powerful even when compared to equally-
sedentary but healthy individuals with comparable limb muscle mass, indicating that the muscular 
deficits in HFrEF are not simply due to physical inactivity or muscle atrophy [6]. Instead, recent 
studies have demonstrated that the muscle dysfunction found in HF patients is characterised by 
derangements at the molecular level [7-10]. In HF, decreased muscle power also predicts 
increased mortality [11]. In one study of more than 100 HF patients, decreased skeletal muscle 
power was a more powerful predictor of mortality than V̇O2peak (Figure 1) [12]. Even in young 
healthy adults, lower muscle power predicts increased mortality. In a study of more than 1 million 
young men, all-cause mortality was a striking 122.3 per 100,000 person-years in the weakest 
versus 5.6 per 100,000 person-years in the strongest men [13]. Clearly, muscle power is an 
extremely important target for treatment in HF, yet is one that is not presently addressed by any 
standard medications or therapies.  
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NO deficiency — a key derangement in HFrEF.  
Numerous factors account for the decline in exercise performance in HFrEF patients. These 
include, but are not limited to, increased skeletal muscle breakdown, increased oxidative stress, 
inflammation, and hypoperfusion. An excellent review of the many mechanisms that affect skeletal 
muscle function in heart failure is provided by Schulze and Toth in, Heart Failure, A Companion 
to Braunwald’s Heart Disease [14].  It is beyond the scope of this mini-review to detail all of these 
factors; instead, we will focus on one key molecular factor contributing to these derangements  
low NO bioavailability [15]. The evidence for decreased NO bioavailability is manifold.  Breath NO 
levels are lower in patients with HFrEF compared with healthy individuals [16].  Decreased plasma 
levels of nitrosothiols and cyclic guanosine monophosphate (cGMP) — a key mediator of NO 
effects — also indicate low NO bioavailability in HFrEF [17].  NO stimulates guanyl cyclase (sGC) 
to increase cGMP production, which has opposite effects in smooth and skeletal muscle.  In 
smooth muscle (e.g., in the arterial wall), NO causes vasodilation via stimulation of sGC and 
hence increased cGMP.  In skeletal muscle, NO stimulation of sGC and upregulation of cGMP 
increases force of contraction [18] and the capacity for mitochondrial fatty acid oxidation [19].  To 
be sure, there are other pathways by which NO affects muscle.  It is evident that NO deficiency 
could cause a decrease in cGMP and consequent impairments in vasodilation and aerobic 
exercise capacity, as well as decreased muscle power. Indeed, patients with HFrEF have 
impaired endothelial function, as was demonstrated by human cardiac catheterization studies in 
the 1990s [17]. Importantly, this impaired endothelial function in HFrEF is independently 
associated with an increased incidence of HF hospitalization, cardiac transplantation, and death 
[20].  
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 The mechanisms by which NO bioavailability is reduced in HFrEF include both decreased 
production and enhanced degradation of NO [17].  In HFrEF, the activity of the endothelial isoform 
of NO synthase, eNOS, is decreased [17], while the levels of reactive oxygen species (ROS) that 
degrade NO are increased [21].  ROS levels are higher, at least in part, due to decreased 
antioxidant defenses [17]. Moreover, this increased oxidative stress in the left ventricle is 
correlated with the severity of HFrEF [22].  Studies in animal models further support the idea that 
decreased NO bioavailability is pathophysiologically linked to HF, rather than simply associative. 
These murine studies demonstrate a protective effect of enhanced production of NO (via eNOS 
overexpression) against HF development. Consistent with this premise that eNOS is beneficial, 
animal models that are deficient in eNOS are more susceptible to HF development, left ventricular 
hypertrophy, and hypertension [17]. Thus, increasing NO bioavailability in HFrEF patients is an 
attractive target for the amelioration of HFrEF symptoms.  
 
Nitric oxide (NO) production: the main metabolic pathways. 
 
There are 3 main pathways for increasing NO production, as shown in Figure 2. The 
pharmacologic, organic nitrate pathway has the longest history in Western medicine, with drugs 
such as nitroglycerin (glyceryl trinitrate) used for over 150 years to ameliorate angina and 
HFrEF symptoms due to its vasodilatory effects. However, it wasn’t until almost 100 years later 
that scientists discovered that NO was the primary molecule responsible for the vasodilatory 
effects.  Nitroglycerin generates NO through mitochondrial aldehyde dehydrogenase (ALDH-2) 
[23] by generating the intermediary products nitrate (NO3-) and 1,2- glyceryl dinitrate; the NO3- in 
the mitochondria is subsequently reduced to NO and/or converted to S-nitrosothiol. An 
important disadvantage of this pathway is that prolonged organic NO3- treatment often induces 
tolerance (i.e., impaired vasodilation response to nitroglycerin treatment) and cross-tolerance 
(i.e., impaired endothelium-dependent vasodilation), with oxidative stress playing an important 
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role.  Data suggest that inactivation of a key enzyme in the processing of nitroglycerin — 
mitochondrial ALDH-2 — by reactive oxygen species (ROS) is central to tolerance and cross-
tolerance [24].  Chronic nitroglycerin treatment can also lead to supersensitivity to 
vasoconstrictive molecules through chronic activation of protein kinase C [23]. Different organic 
nitrates have varying propensities for inducing tolerance [25] and their use may be limited by 
side effects such as severe headaches, hypotension, and rebound vasoconstriction, a 
phenomenon that occurs following nitrate withdrawal and which may be attributable to coronary 
vasoconstriction.       
 A second pathway by which the body can synthesize NO is the endogenous nitric oxide 
synthase (NOS) pathway (Figure 2) discovered by Furchgott, Ignarro, and Murad, who were 
awarded the 1998 Nobel Prize in Physiology or Medicine [26] “for their discoveries concerning 
nitric oxide as a signaling molecule in the cardiovascular system” (Nobelprize.org).  In this 
endogenous pathway, NO is synthesized enzymatically from the conditionally essential amino 
acid L-arginine, oxygen, and NADPH by three NOS isoforms: neuronal NOS (nNOS or NOS1), 
inducible NOS (iNOS or NOS2), and endothelial NOS (eNOS or NOS3).  nNOS and eNOS are 
calcium dependent.  In addition to NO, L-citrulline is produced and can be recycled to generate 
de novo arginine. Co-factors necessary in this process include tetrahydrobiopterin (BH4), flavin 
adenine dinucleotide (FAD), flavin mononucleotide (FMN), and heme. There are limitations to 
this pathway, however. First, it requires oxygen.  Thus, NO production by NOS enzymes 
decreases with ischemic duration, as shown by Giraldez et al. [27].  Second, NOS activity 
diminishes as pH decreases, with a marked lowering at pH <7.0.  Not only do 
abnormal/diseased tissues have a pH in this range, but also healthy skeletal muscle that is 
engaged in vigorous exercise experiences pH decreases into this range [28].  Interestingly, the 
third NO production pathway works best in ischemic and/or acidic conditions, and thus is a 
perfect compliment to the NOS pathway.  
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 The third NO metabolic pathway is the dietary or inorganic nitrate pathway (also referred 
to as the enterosalivary pathway). Ironically, though this pathway likely has existed for millennia, 
it wasn’t discovered until ~1994.  There is a suggestion, however, that the effects of this dietary 
nitrate pathway were known in ancient China, where it was noticed that KNO3 was useful for 
“treating symptoms…such as acute heart pains” [29]. In this ‘enterosalivary’ pathway, NO is 
produced through sequential reduction of inorganic dietary nitrate [29] independently of NOS, 
beginning with inorganic NO3- from dietary sources (e.g., beets and dark green leafy 
vegetables). Reduction to nitrite (NO2-) is facilitated by bacterial nitrate oxidoreductases from 
commensal bacteria in the oral cavity. The very low pH of the stomach also favors the chemical 
reduction of NO3- to NO2-, as well as the reduction of NO2- to NO.  The intestine then absorbs 
the anions, which are taken up by the circulation [29].  Once in the circulation, the skeletal 
muscle may take up nitrate and serve as an important ‘reservoir’ of nitrate (Figure 2) [30].  
Further acidic reduction of NO2- to NO occurs in tissues, catalyzed by deoxy-hemoglobin, 
deoxy-myoglobin, xanthine oxidoreductase, or other nitrate reductases. Heavily exercising 
skeletal muscle is also a prominent tissue for the final conversion to NO because the metabolic 
conditions are appropriate (i.e., low pH and low pO2) [28].  Of note, this pathway can also move 
in reverse with decreasing acidity and abundant oxygen (e.g., nitrite can be made from NO).  
Recent data from Omar et al. show that this hypoxia-driven reduction of NO2- to NO can occur in 
small resistance arterioles, thus facilitating tissue perfusion [31]. Thus, this pathway is especially 
beneficial in hypoxia and ischemia. Although an estimated 75% of circulating nitrate is excreted 
by the kidneys or exhaled as NO, there is active re-uptake of approximately 25% of circulating 
nitrate by the salivary glands [32], which then secrete NO3-, thus re-starting the enterosalivary 
cycle of nitrate reduction in the oral cavity.  The fact that the body actively recycles nitrate in this 
pathway underscores its biological importance.  Indeed, estimates suggest that a significant 
fraction of the body’s NO is derived from this exogenous pathway.  It is also interesting to note 
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that Omar et al. [31] showed that supraphysiologic/near-physiologic levels of inorganic NO2- can 
be reduced to NO in normoxic – but not hypoxic or hyperoxic – conditions in conduit arteries. In 
short, the inorganic NO3- pathway for NO generation is complex, likely has been operative in 
mankind for millennia, and functions in conditions not conducive to NO production by NOS.  
There are also several other specific advantages of this inorganic nitrate pathway as a source 
for NO generation over the other two pathways.  
 
Advantages of the inorganic nitrate pathway as a source of NO for the cardiovascular 
system. 
The exogenous inorganic nitrate pathway for generation of NO has distinct advantages over the 
NOS pathway and over organic nitrate drugs (see Table 1).  As mentioned above, the inorganic 
nitrate pathway functions best in ischemic and acidic conditions, particularly at the arteriolar 
level [31], thus facilitating NO-related effects such as vasodilation and skeletal muscle 
contraction, particularly in stressed or diseased tissues.  The NOS pathway, by contrast, is O2-
dependent and therefore does not function well under these conditions.  The inorganic pathway 
also has a slower onset of action than some organic nitrates, which may contribute to fewer 
reports of hypotension, flushing, and severe headaches [33-36].  There are also reports that 
inorganic nitrate treatment lessens mitochondrial oxidative stress [37], whereas organic nitrates, 
such as nitroglycerin, increase it [23].  As mentioned above, this increase in oxidative stress and 
other mechanisms cause tolerance with continuous use of organic nitrates such as nitroglycerin.  
Importantly, there are data from studies of continuous infusion of inorganic nitrite in nonhuman 
primates [38] and in humans [39] showing that there is no tolerance to inorganic nitrite.  A recent 
study by Andrew Murray’s group demonstrated another benefit of the inorganic pathway:  
dietary inorganic nitrate increases arginine availability for the NOS pathway by suppressing 
cardiac arginase expression and increasing tissue L-arginine in both normoxic and hypoxic 
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conditions [37].  Recent data from Chirinos et al. in patients with HF with preserved ejection 
fraction also show that inorganic nitrate reduces the left ventricular load late in systole, which is 
caused by reflected waves from the arterial tree.  Inorganic nitrate administration shifts the 
reflected wave later into diastole, thereby improving coronary perfusion pressure [40]. Table 1 
also includes advantages of inorganic nitrate therapy over sildenafil and other 
phosphodiesterase 5 (PDE5) inhibitors; these drugs also increase cGMP, induce vasodilation, 
and have other cGMP-mediated effects, but do not increase NO.  Thus, there are several 
advantages of the inorganic nitrate pathway over other pathways for NO production, and 
eventually, cGMP amplification.  These advantages make inorganic nitrate an attractive 
potential therapeutic agent for increasing NO, especially in patients who have reduced NO 
bioavailability – such as those with HFrEF. 
 
Inorganic nitrate effects on exercise performance in patients with HFrEF.   
Preliminary data show that inorganic nitrate improves muscle power and NO bioavailability.   In 
one small, double-blind, placebo-controlled study, 11.2 mmol of inorganic nitrate, given in the 
form of concentrated beetroot juice, increased quadriceps muscle power within two hours after a 
single dose [34].  Peak muscle power was increased by ~11% at the highest movement velocity 
tested.  The inorganic nitrate consumption was accompanied by a ~20 fold increase in plasma 
nitrate levels, as well as a 35-50% increase in breath NO levels [34].  Calculated maximal 
velocity of contraction and maximal power were also significantly increased after ingestion of 
dietary inorganic nitrate (13 and 12%, respectively) [34].  The improvement in muscle power 
seen after a single dose of inorganic nitrate is comparable to that which would be expected to 
result from ~2 to 3 months of resistance exercise training [34].  Based on a study by Toth et al. 
[6], in which patients with HFrEF were shown to have less powerful muscle function (even after 
correcting for muscle mass and other variables), the improvements observed after inorganic 
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nitrate treatment would have erased ~1/3 of the HF-related deficit in muscle power [34].  This 
improvement in muscle power after inorganic nitrate therapy contrasts with the lack of an effect 
that standard HF therapies (i.e., beta-adrenergic antagonists, angiotensin-converting enzyme 
inhibitors, angiotensin receptor blockers, and aldosterone antagonists) have on muscle power 
[34].  It is unclear whether inorganic nitrate can also increase myocardial contractile power, as it 
does in skeletal muscle.  Nevertheless, an improvement in skeletal muscle function alone 
should help patients with HFrEF perform many of their activities of daily living because many 
activities rely on muscle power. 
 Results from studies on the effect of inorganic nitrate on aerobic exercise capacity in 
patients with HFrEF are slightly more mixed.  Coggan et al. showed in a small, double-blind, 
placebo-controlled study that dietary inorganic nitrate markedly increased plasma nitrate, 
plasma nitrite, and breath NO levels (by 1469 ± 245%, 105 ± 34%, and 60 ±18%, respectively) 
[41].  Simultaneous with this increase in NO bioavailability, V̇O2peak increased by 8 ± 2% and 
time to fatigue increased by 7 ± 3%.  Exercise efficiency, however, did not change [41].  
Although this increase in V̇O2peak is small, based on outcomes studies, this change in V̇O2peak 
should translate into a ~10% decrease in the annual risk of death or transplant [41, 42].   
 The improvement in V̇O2peak seen in the study by Coggan et al. correlates well with 
results of a study by Kerly et al., in which a single dose of inorganic nitrate enhanced 
incremental shuttle walk test performance in patients with HFrEF by ~18% as compared with 
placebo [43].  Of note, these positive effects on aerobic performance also correlate with a study 
of inorganic nitrate’s effects in HF patients with preserved ejection fraction [36].  A recent study 
by Hirai et al. in male patients, most of whom had ischemic cardiomyopathy, however, did not 
show an improvement in V̇O2peak after repeated dosing of inorganic nitrate [44].  Differences in 
HFrEF etiology, other patient characteristics, or nitrate dosing regimens between studies may 
account for the differences in V̇O2peak results. Although the source of inorganic nitrates was 
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beetroot juice in both the Coggan [41] and Hirai [44] studies, the inorganic nitrate dose that was 
ingested 2 hours before exercise testing was 11.2 mmol in the Coggan study and 6.45 mmol in 
the Hirai study. The difference in V̇O2peak results does not appear to be due to differences in 
HFrEF severity or ejection fraction. 
 
Mechanisms of action of NO relating to improved exercise performance in HFrEF. 
There are several NO-mediated effects on muscle contractile function [18].  Because the net 
effect of inorganic nitrate ingestion in patients with HFrEF is an improvement in muscle 
contractile function, the NO-related pathways that increase muscle contractile function must 
‘win’ over the NO-related pathways that would decrease muscle function.  As mentioned above, 
NO increases sGC activity, thereby increasing cGMP. This leads to an increase in the speed of 
muscle shortening, and hence an increase in power [18].  Increased NO availability can also 
result in nitrosylation of the ryanodine receptor on the sarcoplasmic reticulum, which opens this 
channel [45].  This may result in an increase in calcium release by the sarcoplasmic reticulum 
and subsequent enhancement of both maximal muscle contraction velocity and power.  Other 
NO-related effects (e.g., nitrosylation of troponin I [46] or myosin [47] that would be expected to 
have a negative effect on muscle contractile function appear to be weaker than these positive 
effects.  The sum of these pleiotropic NO-related effects in vivo in patients with HFrEF appears 
to result in increased muscle power, which should translate into improved functional capacity. 
 Several NO-mediated mechanisms also likely contribute to the general improvement in 
aerobic capacity after inorganic nitrate administration.  Enhanced efficiency of mitochondrial 
oxidative phosphorylation is one mechanism implicated in the reduced oxygen costs of exercise 
[48-50].  The increase in V̇O2peak described by Coggan et al. in patients with HFrEF likely 
resulted from an increase in cardiac output and/or aterio-venous O2 difference at peak exercise 
[41].  In that study, peak diastolic blood pressure trended lower and heart rate trended higher 
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after inorganic nitrate ingestion, suggesting a higher cardiac output accompanying lower 
peripheral vascular resistance [41].  Since NO is known to be the original “endothelium relaxing 
factor”, as coined by Furchgott, it is reasonable to conclude that the arteriolar vasodilating 
effects of NO may contribute to an improvement in cardiac output and, hence, V̇O2peak. Studies 
of infusions of inorganic nitrite in patients with HFrEF corroborate this, as they show that 
increased forearm blood flow increases in the infused arm [39].  There are also data from 
animal models of NOS manipulation and in vitro studies that indicate that NO from NOS may 
also have direct, positive cardiac lusitropic, inotropic, and/or chronotropic effects distinct from 
responses to vasodilation.  These effects were detailed in a review by Massion et al. [51].  Data 
from patients with heart failure with preserved ejection fraction show that inorganic nitrate, in 
contrast to organic nitrates, can also lessen late systolic pulsatile left ventricular load.  Whether 
one or all of these direct cardiac and pulsatile load effects are active in patients with HFrEF 
remains unclear.   
  
Summary – Conclusions 
NO is a powerful radical with pleiotropic effects.  It is of particular therapeutic interest in the 
treatment of HFrEF because NO bioavailability is low in HFrEF patients and is thought to be a 
key mediator of HF pathophysiology.  There are three main pathways that can be leveraged to 
increase NO bioavailability.  The last to be discovered, the inorganic nitrate pathway, has 
several advantages over the endogenous and organic pharmacologic pathways, as well as over 
PDE5 inhibitors. Inorganic nitrates have been shown in most small clinical studies to improve 
exercise performance – both muscle power and aerobic exercise performance.  A larger study, 
the INIX-HF trial (NCT02797184), is now underway to perform the studies necessary and 
sufficient to set up a multicenter study of the effectiveness of inorganic nitrate for the 
improvement of exercise performance and quality of life in patients with HFrEF. 
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Figure Legends 
 
Figure 1.  Muscle power as a predictor of survival in patients with HFrEF [12].  Kaplan Meier 
lifetime analysis of survival stratified by peak torque index of the knee flexor muscles at a cut-off 
point of 68 N-m x 100 per kg body weight. 
 
Figure 2.  The main pathways for nitric oxide (NO) production. The dietary pathway (starting at 
upper left) utilizes inorganic nitrates and is facilitated by lower pO2 and pH.  Ingestion of nitrate-
containing foods, especially high-nitrate foods such as beetroot are the source of the inorganic 
nitrate (NO3-) start this pathway. NO3- is reduced to nitrite (NO2-) by reductases or acidic 
conditions and facilitated by oxyheme proteins.  Then NO2 is reduced to NO under the 
appropriate conditions. Importantly, skeletal muscle can serve as a ‘reservoir’ for nitrate [30]. As 
shown by the dashed arrows, this pathway can also ‘run in reverse’ with NO being used to 
create NO2- and then NO3- given the appropriate conditions. 
*Note:  NO3- can be taken up from the circulation into the salivary glands and go through this 
reduction pathway again in what is known as ‘the enterosalivary pathway.’  
The endogenous pathway (lower left) uses NO synthase and oxygen to create citrulline and NO. 
An abbreviated depiction of the organic nitrate pathway (lower right) shows the production of 
NO derived from pharmacologic sources, such as nitroglycerin.   
ALDH-2 = aldehyde dehydrogenase, P450 = cytochrome P450.   
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Table 1. Comparison of the inorganic NO3- pathway with other sources of NO and/or cGMP 
Other sources of NO/cGMP Advantage of inorganic NO3- 
L-arginine* 
 Not dependent on NO synthase (NOS) 
 Functions well in acidic tissues 
 Functions well in ischemic tissues; does not require 
molecular oxygen 
Organic, pharmacologic nitrates 
(e.g., nitroglycerin)** 
 Does not cause tolerance 
 Does not increase reactive oxygen species (ROS) 
 May be less likely to cause hypotension† 
 May be less likely to cause flushing or headache† 
 Decreases left ventricular late systolic load  
 Does not cause cross-tolerance with nitroglycerin [39] 
Phosphodiesterase 5 inhibitors 
(e.g., sildenafil) 
 May be less likely to cause hypotension†  
 May be less likely to cause flushing or headache† 
 Less likely to cause retinal dysfunction and vision 
changes through inhibition of PDE6 
 
*The substrate used for NOS-related production of NO. 
**Not all pharmacologic nitrates are prone to these same disadvantages or to the same degree 
(see review by Munzel et al. [52]). 
†These symptoms were not observed in our preliminary studies of HFrEF patients treated with 
11.2 mmol of inorganic nitrate in the form of beetroot juice [34, 35, 41], and inorganic nitrate 
does not cause significant cerebrovascular dilation in HF with preserved ejection fraction [40]. 
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Highlights 
 
 Low nitric oxide (NO) likely contributes to exercise intolerance in heart failure. 
 
 The inorganic nitrate pathway has distinct advantages over other sources of NO.  
 
 Dietary inorganic nitrate, such as in beetroot juice, is chemically reduced to nitrite and 
then NO.  
 
 Inorganic nitrate may improve both muscle power and aerobic exercise performance. 
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